Rome IV Criteria Calculator- Free DGBI Diagnostic Screening Tool

About This Rome IV Criteria Diagnostic Screening Calculator

This Rome IV criteria calculator is designed for patients, clinicians, researchers, and medical students who need to systematically evaluate gastrointestinal symptoms against the internationally recognized Rome IV diagnostic framework for disorders of gut-brain interaction (DGBI). The tool screens for the most clinically significant adult diagnoses including irritable bowel syndrome (IBS) with IBS-C, IBS-D, IBS-M, and IBS-U subtyping, functional dyspepsia with postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) subtypes, functional constipation, functional diarrhea, and functional abdominal bloating and distension.

The calculator applies the exact diagnostic criteria published by the Rome Foundation in May 2016, including the specific symptom frequency thresholds, duration requirements (3 months active with 6-month onset), and logical criterion combinations required for each diagnosis. It incorporates the Bristol Stool Form Scale for IBS subtype classification and screens for alarm features (red flags) that would warrant further investigation before a DGBI diagnosis is considered. All diagnostic logic follows the peer-reviewed criteria from Gastroenterology journal’s 2016 Rome IV supplement.

Results are presented through three complementary visualizations: traffic light diagnostic cards with green (criteria met), amber (partial criteria), and red (not met) status indicators showing individual criterion fulfillment; a radar chart displaying your symptom assessment score across all six diagnostic domains simultaneously for quick pattern recognition; and a running criteria checklist in the sidebar that updates in real time as you answer each question. The calculator also detects when multiple diagnoses overlap, reflecting Rome IV’s recognition that concurrent DGBIs are common and clinically important.

Rome IV Criteria Calculator: Complete Guide to Diagnosing Disorders of Gut-Brain Interaction

Disorders of gut-brain interaction (DGBI), formerly known as functional gastrointestinal disorders (FGIDs), affect an estimated 40% of the global population. These conditions, which include irritable bowel syndrome (IBS), functional dyspepsia, functional constipation, and dozens of other diagnoses, are among the most common reasons patients seek care from gastroenterologists and primary care physicians worldwide. Despite their prevalence and significant impact on quality of life, diagnosing these disorders has historically been challenging because they lack identifiable structural or biochemical abnormalities on standard diagnostic testing.

The Rome IV criteria, published in May 2016 by the Rome Foundation, represent the current gold standard for diagnosing these conditions. Developed through a consensus process involving more than 120 international experts using the Delphi method, Rome IV provides standardized symptom-based diagnostic criteria for 33 adult and 17 pediatric functional gastrointestinal disorders. This calculator implements the Rome IV diagnostic criteria across all major adult disorder categories, allowing clinicians, researchers, and patients to systematically evaluate gastrointestinal symptoms against the established diagnostic framework.

What Are the Rome IV Criteria?

The Rome criteria are a set of evidence-based, expert-consensus diagnostic guidelines created to classify and diagnose functional gastrointestinal disorders. The name derives from the city where international gastroenterology experts first convened in 1988 to develop standardized diagnostic approaches for conditions that could not be explained by structural or biochemical abnormalities. Since that initial meeting, the criteria have undergone four major revisions: Rome I (1994), Rome II (1999), Rome III (2006), and Rome IV (2016).

Rome IV introduced several important conceptual changes. The term “functional gastrointestinal disorders” was replaced with “disorders of gut-brain interaction” (DGBI) to better reflect the current understanding of pathophysiology. This new terminology acknowledges that these conditions involve complex interactions between motility disturbance, visceral hypersensitivity, altered mucosal and immune function, changes in gut microbiota composition, and altered central nervous system processing. The shift away from the word “functional” was also intended to reduce the stigma that patients with these conditions often experience.

Rome IV Classification System: Six Anatomic Domains

Rome IV organizes adult disorders of gut-brain interaction into six anatomic domains, each containing multiple specific diagnoses. Understanding this classification system is essential for accurate diagnosis, as symptoms from different domains may overlap and patients may meet criteria for disorders in multiple categories simultaneously.

Category A encompasses esophageal disorders, including functional chest pain, functional heartburn, reflux hypersensitivity, globus sensation, and functional dysphagia. These diagnoses require exclusion of structural esophageal pathology, gastroesophageal reflux disease, and eosinophilic esophagitis as the cause of symptoms. Category B covers gastroduodenal disorders, which include functional dyspepsia and its subtypes (postprandial distress syndrome and epigastric pain syndrome), belching disorders, nausea and vomiting disorders (chronic nausea vomiting syndrome, cyclic vomiting syndrome, and cannabinoid hyperemesis syndrome), and rumination syndrome.

Category C addresses bowel disorders, the most commonly diagnosed group. This includes irritable bowel syndrome with its four subtypes (IBS-C, IBS-D, IBS-M, and IBS-U), functional constipation, functional diarrhea, functional abdominal bloating and distension, unspecified functional bowel disorder, and opioid-induced constipation. A key conceptual change in Rome IV is the recognition that these bowel disorders exist on a spectrum rather than as discrete entities, with patients potentially moving between diagnoses over time.

Category D includes centrally mediated disorders of gastrointestinal pain, specifically centrally mediated abdominal pain syndrome (CAPS, formerly functional abdominal pain syndrome) and narcotic bowel syndrome (opioid-induced GI hyperalgesia). Category E covers gallbladder and sphincter of Oddi disorders, including functional gallbladder disorder, functional biliary sphincter of Oddi disorder, and functional pancreatic sphincter of Oddi disorder. Category F encompasses anorectal disorders such as fecal incontinence, levator ani syndrome, unspecified functional anorectal pain, proctalgia fugax, and functional defecation disorders.

Irritable Bowel Syndrome (IBS): The Most Common DGBI

Irritable bowel syndrome is the most prevalent disorder of gut-brain interaction, affecting approximately 4-5% of the global population according to the Rome Foundation Global Study. The Rome IV diagnostic criteria for IBS require recurrent abdominal pain, on average, at least 1 day per week in the last 3 months, associated with two or more of the following: pain related to defecation, a change in stool frequency, or a change in stool form (appearance). This represents a significant change from Rome III, which required pain or discomfort at least 3 days per month. The removal of “discomfort” and increase in pain frequency threshold means Rome IV identifies a more severe subset of patients.

IBS is subtyped based on predominant stool pattern using the Bristol Stool Form Scale (BSFS). IBS with predominant constipation (IBS-C) is diagnosed when more than 25% of abnormal bowel movements are BSFS types 1-2 (hard or lumpy) and fewer than 25% are BSFS types 6-7 (loose or watery). IBS with predominant diarrhea (IBS-D) applies when more than 25% of abnormal bowel movements are BSFS types 6-7 and fewer than 25% are types 1-2. IBS with mixed bowel habits (IBS-M) is diagnosed when more than 25% of abnormal bowel movements are both types 1-2 and types 6-7. If the pattern does not fit any of these three subtypes, the classification is IBS unclassified (IBS-U).

Functional Dyspepsia and Its Subtypes

Functional dyspepsia is another extremely common DGBI, affecting approximately 7-8% of the global population. Rome IV defines functional dyspepsia as the presence of one or more of four cardinal symptoms: bothersome postprandial fullness, bothersome early satiation, bothersome epigastric pain, and bothersome epigastric burning. The symptoms must be severe enough to impact usual activities, and no evidence of organic, systemic, or metabolic disease should be found on routine investigations including upper endoscopy.

Functional dyspepsia is subdivided into postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS), though these subtypes frequently overlap. PDS is diagnosed when patients experience bothersome postprandial fullness and/or bothersome early satiation at least 3 days per week. EPS requires bothersome epigastric pain and/or bothersome epigastric burning at least 1 day per week. The distinction between these subtypes is clinically important because they may respond to different treatment approaches, with PDS often responding better to prokinetic agents and EPS to acid-suppressing medications.

Functional Constipation

Functional constipation is diagnosed using Rome IV criteria when patients experience two or more of the following symptoms during at least 25% of defecations: straining, lumpy or hard stools (BSFS 1-2), sensation of incomplete evacuation, sensation of anorectal obstruction or blockage, manual maneuvers to facilitate defecation, or fewer than three spontaneous bowel movements per week. Critically, loose stools must be rarely present without the use of laxatives, and there must be insufficient criteria for a diagnosis of IBS (meaning the patient should not have significant abdominal pain associated with their constipation symptoms).

Rome IV acknowledges that functional constipation and IBS-C exist on a continuum rather than as entirely separate disorders. Some patients may transition between these diagnoses over time as the prominence of pain changes relative to their constipation symptoms. This spectrum concept is one of the important conceptual advances in Rome IV compared to earlier iterations.

Functional Diarrhea and Functional Bloating

Functional diarrhea is characterized by loose or watery stools occurring in more than 25% of bowel movements, without predominant abdominal pain or bothersome bloating. Patients meeting criteria for IBS-D should be excluded from this diagnosis. Similarly, functional abdominal bloating and distension is diagnosed when recurrent bloating (subjective sensation) and/or distension (objective visible increase in abdominal girth) occur on average at least 1 day per week, and these symptoms predominate over other gastrointestinal symptoms. Patients must have insufficient criteria for IBS, functional constipation, functional diarrhea, or postprandial distress syndrome.

Esophageal Disorders: From Chest Pain to Dysphagia

The esophageal disorders category in Rome IV includes five diagnoses. Functional chest pain requires retrosternal chest pain or discomfort that is not explained by cardiac causes, gastroesophageal reflux, or a major esophageal motor disorder. Functional heartburn involves a burning retrosternal sensation or pain without evidence that reflux or eosinophilic esophagitis is the cause. Reflux hypersensitivity, a new diagnosis in Rome IV, applies when heartburn or chest pain is triggered by physiologic levels of reflux in patients with normal endoscopy and normal acid exposure. Globus is the persistent or intermittent non-painful sensation of a lump or foreign body in the throat that occurs between meals. Functional dysphagia is the sense of abnormal bolus transit through the esophageal body without structural or motor causes.

Nausea, Vomiting, and Belching Disorders

Rome IV recognizes several gastroduodenal disorders beyond functional dyspepsia. Chronic nausea vomiting syndrome requires bothersome nausea occurring at least 1 day per week and/or one or more vomiting episodes per week, with exclusion of self-induced vomiting, eating disorders, regurgitation, and rumination. Cyclic vomiting syndrome involves stereotypical episodes of vomiting regarding onset and duration, with at least three discrete episodes in the prior year and two in the past 6 months occurring at least 1 week apart. Cannabinoid hyperemesis syndrome, a new addition in Rome IV, presents similarly but requires ongoing cannabis use.

Belching disorders are classified as excessive supragastric belching (from the esophagus) or excessive gastric belching (from the stomach), both requiring bothersome belching more than 3 days per week. Rumination syndrome involves persistent or recurrent regurgitation of recently ingested food that may be re-chewed, re-swallowed, or expectorated, and is not preceded by retching.

Centrally Mediated Pain Disorders and Anorectal Conditions

Centrally mediated abdominal pain syndrome (CAPS) represents one of the most severe DGBIs and is characterized by continuous or nearly continuous abdominal pain that has no or only occasional relationship to physiologic events such as eating, defecation, or menses. The pain must limit some aspect of daily functioning and not be explained by another structural or functional gastrointestinal disorder. CAPS is typically associated with significant psychosocial comorbidity.

Narcotic bowel syndrome, also called opioid-induced GI hyperalgesia, is diagnosed in patients with chronic or frequently recurring abdominal pain treated with acute or chronic narcotics, where the pain worsens or incompletely resolves with continued or escalating opioid dosages. Rome IV also includes opioid-induced constipation as a new diagnosis, recognizing the high prevalence of constipation in patients on opioid therapy.

Anorectal disorders include fecal incontinence (recurrent uncontrolled passage of fecal material for at least 3 months), levator ani syndrome (chronic or recurrent rectal pain or aching lasting at least 30 minutes, with tenderness during posterior traction on the puborectalis), proctalgia fugax (recurrent episodes of localized rectal pain lasting seconds to minutes), and functional defecation disorders diagnosed through anorectal manometry or other physiologic testing.

How the Rome IV Criteria Calculator Works

This calculator systematically evaluates your reported symptoms against the Rome IV diagnostic criteria for major disorders of gut-brain interaction. It guides users through a structured symptom assessment organized by anatomic domain and applies the specific frequency, duration, and exclusion criteria defined by the Rome Foundation. The calculator covers the most clinically significant adult DGBI diagnoses including IBS and its subtypes, functional dyspepsia (PDS and EPS), functional constipation, functional diarrhea, functional bloating, and key esophageal, gastroduodenal, and centrally mediated disorders.

Users begin by answering questions about symptom duration (whether symptoms have been present for at least 6 months) and then proceed through domain-specific symptom questionnaires. Each question corresponds to a specific criterion required for diagnosis. The calculator applies the appropriate frequency thresholds and logical combinations to determine which diagnoses are met, potentially met (when some but not all criteria are fulfilled), or not met. Results are displayed with clear explanations of which specific criteria were satisfied and which were not, along with clinical guidance about next steps.

Changes from Rome III to Rome IV

Understanding the key differences between Rome III and Rome IV helps clinicians and researchers appreciate why diagnostic results may differ when applying the updated criteria. For IBS, the most impactful change was replacing “pain or discomfort” with “pain” alone and increasing the minimum frequency from 3 days per month to at least 1 day per week. Studies have shown that approximately 85% of patients meeting Rome III criteria for IBS also meet Rome IV criteria, but 15% lose their diagnosis under the stricter criteria. Those who retain the diagnosis tend to have more severe symptoms and greater psychological comorbidity.

For functional dyspepsia, Rome IV introduced the requirement that symptoms be “bothersome” (severe enough to impact usual activities), raising the threshold from Rome III. The frequency requirements for PDS were also increased to at least 3 days per week. Functional bowel disorders are now explicitly described as existing on a spectrum, and Rome IV recognizes that bloating and distension can accompany any functional bowel disorder. Several new diagnoses were added including reflux hypersensitivity, cannabinoid hyperemesis syndrome, and opioid-induced constipation. The biopsychosocial model was expanded to include roles for the gut microbiome, immune activation, and altered barrier function.

The Bristol Stool Form Scale in IBS Subtyping

The Bristol Stool Form Scale (BSFS) is integral to IBS subtyping under Rome IV. This validated seven-point scale classifies stool consistency from Type 1 (separate hard lumps, like nuts, difficult to pass) through Type 7 (watery, no solid pieces, entirely liquid). Types 1 and 2 indicate constipation, types 3 and 4 are considered normal, and types 6 and 7 indicate diarrhea. Type 5 represents soft blobs with clear-cut edges that are passed easily.

A key change in Rome IV is that IBS subtyping is now based on stool form on days when bowel movements are abnormal, rather than on all days as in Rome III. This change was made because many IBS patients have extended periods of normal stool consistency. The subtype should be determined when the patient is not taking medications that treat bowel symptoms. Rome IV also emphasizes that IBS subtypes are not separate conditions and that patients may transition between subtypes over time as their predominant bowel pattern changes.

Global Prevalence and Population Considerations

The Rome Foundation Global Epidemiology Study, published in 2021, provided the most comprehensive worldwide data on DGBI prevalence. The study surveyed over 73,000 adults across 33 countries on six continents and found that more than 40% of participants met criteria for at least one DGBI. Prevalence varied significantly by region, with functional dyspepsia affecting approximately 7.2% of the global population, IBS affecting 4.1%, functional constipation 11.7%, and functional diarrhea 4.7%.

Cross-cultural validation studies have shown that the Rome IV criteria perform differently across ethnic populations. The original Rome criteria were developed primarily in Western populations, and Rome IV made a deliberate effort to be more multicultural in its approach, adding a dedicated chapter on multicultural aspects for the first time. Healthcare providers globally should be aware that symptom reporting patterns may vary across cultures, and the specific thresholds in the criteria may not perform identically in all populations. Alternative regional diagnostic frameworks exist, including guidelines from the Asian Neurogastroenterology and Motility Association and the British Society of Gastroenterology, which may complement the Rome IV criteria in specific populations.

Alarm Features and Red Flags

Before applying the Rome IV criteria, clinicians should evaluate for alarm features (red flags) that suggest organic disease rather than a DGBI. These warning signs include onset of symptoms after age 50 without prior colon cancer screening, unintentional weight loss, rectal bleeding or melena, nocturnal symptoms that wake the patient from sleep, a family history of colorectal cancer or inflammatory bowel disease, anemia, fever, and a palpable abdominal mass. The presence of any alarm feature warrants thorough investigation to exclude organic pathology before a DGBI diagnosis is considered.

It is important to note that the Rome IV criteria are designed as a “positive diagnosis” system rather than a diagnosis of exclusion. While organic disease must be excluded, this does not require exhaustive testing in every patient. Appropriate evaluation should be guided by the clinical context, patient demographics, and specific symptom pattern. Studies have shown that a diagnosis of IBS made using Rome IV criteria with limited, targeted investigations is both safe and durable, with missed organic disease occurring in only approximately 1% of cases during long-term follow-up.

Overlap Between Multiple DGBIs

One of the clinical challenges in using the Rome IV criteria is that patients frequently meet diagnostic criteria for multiple disorders simultaneously. Overlap between functional dyspepsia and IBS is particularly common, with studies reporting co-occurrence rates of 20-50%. Similarly, GERD symptoms frequently coexist with functional dyspepsia and IBS. The Rome IV criteria acknowledge these overlaps and do not require that a patient be assigned a single diagnosis. Multiple concurrent DGBI diagnoses may be appropriate and clinically important for guiding comprehensive treatment strategies.

The spectrum model introduced in Rome IV further supports the concept that boundaries between certain diagnoses are not rigid. A patient with IBS-C may transition to functional constipation if abdominal pain resolves, or vice versa. Understanding these dynamic relationships helps clinicians and patients set appropriate expectations about symptom fluctuation and long-term management.

Limitations of the Rome IV Criteria

While the Rome IV criteria represent the best available diagnostic framework for DGBIs, they have recognized limitations. The more restrictive nature of Rome IV compared to Rome III means that some patients with clinically significant symptoms may not meet formal diagnostic criteria, particularly those with mild IBS or intermittent symptoms. Research has shown that nearly 20% of patients judged by clinicians to have IBS do not formally meet Rome IV criteria. Proposed modifications for clinical practice include relaxing the minimum symptom frequency threshold and removing the 6-month minimum duration requirement, provided that symptoms are bothersome enough to prompt medical consultation.

The criteria are also inherently subjective, relying entirely on patient-reported symptoms. Patients may interpret symptom descriptions differently, and cultural factors can influence how symptoms are reported. The frequency thresholds (such as “at least 1 day per week”) require patients to accurately recall and quantify their symptom patterns, which can be challenging. Additionally, the criteria do not account for symptom severity, meaning a patient with mildly bothersome daily symptoms and a patient with severely debilitating daily symptoms would both meet the same diagnostic criteria.

Clinical Applications and Future Directions

The Rome IV criteria serve multiple important purposes in clinical practice and research. In clinical settings, they provide a standardized framework for making positive diagnoses, reducing unnecessary diagnostic testing, and facilitating communication between healthcare providers. In research, they ensure consistent patient selection for clinical trials and epidemiological studies, enabling comparison of results across studies and populations.

Looking ahead, the Rome Foundation has announced that Rome V is in development. Future iterations are expected to incorporate advances in biomarker research, including potential objective markers for visceral hypersensitivity, altered intestinal permeability, and changes in the gut microbiome. There is also growing interest in integrating patient-reported outcome measures with the diagnostic criteria to better capture symptom severity and impact on quality of life. The continued evolution of the Rome criteria reflects the field’s commitment to improving the lives of the hundreds of millions of people worldwide living with disorders of gut-brain interaction.

Frequently Asked Questions

Conclusion

The Rome IV criteria represent the culmination of nearly three decades of international effort to standardize the diagnosis of disorders of gut-brain interaction. By providing a systematic, evidence-based framework for evaluating gastrointestinal symptoms, these criteria have transformed how clinicians approach, diagnose, and treat some of the most common conditions in gastroenterology. This calculator offers a practical implementation of the Rome IV diagnostic criteria, enabling systematic symptom assessment for major adult DGBIs including IBS and its subtypes, functional dyspepsia, functional constipation, functional diarrhea, and other clinically significant conditions.

While this tool serves as a valuable screening and educational resource, it is essential to remember that the Rome IV criteria are designed to be applied within the context of a comprehensive clinical evaluation. Organic diseases must be excluded through appropriate medical testing, and alarm features should always be assessed before a DGBI diagnosis is confirmed. If your results suggest you may meet criteria for a disorder of gut-brain interaction, take this information to your healthcare provider as a starting point for a thorough clinical discussion and evaluation.